Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.
Daniel Lubetzky invests in health and longevity companies through Camino Partners.
Learn more about Assistant Professor of Psychological Sciences Daniel Forster, PhD, his background and his passion for research and teaching in the Q&A below. Q: Please share your name, title, ...
Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
Hosted on MSN15d
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)In fact, Gilead Sciences (NASDAQ ... first-line treatment for metastatic triple-negative breast cancer. CEO Daniel O'Day told analysts on the Q4 earnings call: As we shared at our HIV analyst ...
Pharmaceutical stock Gilead Sciences is the best performing ... for metastatic triple-negative breast cancer. CEO Daniel O'Day told analysts on the Q4 earnings call: As we shared at our HIV ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback